Genzyme is one of the world’s leading biotechnology companies. Its more than 11,000 employees work in countries throughout the world and are united by a common goal: to make a major positive impact on the lives of people with debilitating diseases.
Since its founding in 1981, Genzyme has grown from a small start-up to a diversified enterprise with 2008 revenues of $4.6 billion. Over the past two decades Genzyme has introduced a number of breakthrough treatments in several areas of medicine, which have provided hope to patients who previously had no viable treatment options. Genzyme products are helping patients in 100 countries.
Today, Genzyme continues to be driven by its commitment to patients. The company is working to develop new medicines, improve its existing therapies, secure approvals for its products around the world, and ensure that patients have access to these treatments. Genzyme, which has its headquarters in Cambridge, Massachusetts, was chosen in 2007 to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.
Contact Details
Buyukdere Cad. No:193 Kat: 3-10
34394 Levent
Istanbul
Turkey
Tel: +90 212 339 59 00
Fax: +90 212 339 59 09
Genzyme Turkey’s general manager discusses diagnosis and treatment access issues for rare diseases, the need for prioritization of patient welfare in all aspects of health policy, and the importance of…
In the world’s 18th largest market, recent pricing struggles have pushed some companies to revaluate their investment approach. Multinational organizations are complying with localization policies but are divided between having…
Arven Pharmaceuticals is the Turkish R&D-based company behind the first biosimilar drug developed and manufactured from cell to final product in the country, and the first patented and produced dry…
Ercin Kugu, CSL Behring’s general manager for Turkey and Israel, highlights the rare disease company’s footprint in Turkey, explains the different regulatory framework in the country for plasma products, and…
Boehringer Ingelheim (BI), the largest private pharma company in the world, has become the latest Big Pharma player to commit to Turkish localization after announcing a contract manufacturing partnership with…
After being present in the Turkish market for more than 28 years, MSD seems confident that it will be able to seize upcoming opportunities due to the country’s high prevalence…
Over a decade ago, GE Healthcare selected Turkey as an international operational base for its Eastern and Africa Growth Markets (EAGM) and 84 countries are managed from Turkey today. Nael…
Dogan Taskent, board member of the Swiss Chamber of Commerce in Turkey, highlights Turkey’s successful response to the COVID-19 pandemic, how the local R&D ecosystem collaborated, often for free, to…
Amgen, the American biotech giant, established a direct presence in Turkey in 2010 by acquiring a local generics manufacturer for US 700 million. Its general manager in the country, Güldem…
Few Turkish companies are experiencing such a transformational moment as GEN. Just in 2021, the Ankara-based organization made its public debut at the Istanbul Stock Exchange and signed an exclusive…
The president of the Turkish Health Institutes (TUSEB), Dr Erhan Akdoğan, provides a behind-the-scenes look at the development process of Turkovac, the country’s first homegrown COVID-19 vaccine which is currently…
Ersin Erfa, CEO of Centurion, a Turkish manufacturer, discusses the company’s high ambitions, R&D capabilities, and their work on a COVID-19 treatment currently in phase II clinical trials. Erfa explains…
Best known as the company that launched the world’s first “antibody biosimilar,” Celltrion is looking to continue its growth as a global biopharmaceutical company. Its general manager for Turkey, SeokHoon…
See our Cookie Privacy Policy Here
